Explore it now
27th Annual ESGO 2026 Congress
Discover it Now!
ENGOT coordinates and promotes gynaecological cancer clinical trials in Europe
Explore ENGOT
Explore ESGO’s Membership Benefits
Read More
ESGO took a pivotal step toward shaping the future of our field. All ESGO accredited centres in Europe and beyond were invited to join forces, forming the ESGO Consortium of Accredited Centres and sharing real-world clinical data through the ESGO Database platform. Out of those invited, 85 centres signed the Framework Agreement, strengthening scientific collaboration.
The goal of the ESGO Database is to conduct joint clinical research, including the validation of ESGO quality indicators (QI), identification of new QIs, analysis of guidelines adherence, and generation of real-world data in gynaecological oncology.
We are proud to announce that we have successfully closed the pilot project, 'Validation of the ESGO Quality Indicators in Advanced Ovarian Cancer Surgery,' collecting data from over 12,000 patient records. The Database Core Group is currently working on a manuscript, and we anticipate the results will drive scientific progress, enhance quality assurance, and improve patient care in gynaecological oncology.
The findings will also continue to serve as a powerful tool for advocating centralization and subspecialty training, ultimately enhancing patient care.
Looking ahead, ESGO plans to expand the use of this data for future research, including new studies on endometrial cancer surgery. Additionally, there is also a vision to integrate the ESGO Database with ESGO's accreditation process.
Is your center ESGO Accredited? Would you like to be part of this pan-European and beyond vision and help advance care for women with gynecological cancer?
Don't hesitate; reach out to us via database@esgo.org and join the ESGO Consortium!
We are proud to say that to date, 85 centers from around the world have signed the Framework agreement and joined us in this collective effort!
The third closed meeting of the ESGO Consortium was held on February 20, 2025, at the Convention Center "La Nuvola" during the ESGO 2025 Congress in Rome, Italy. The meeting was a great success, with many innovative ideas presented, and the nine winning studies were officially announced during the opening ceremony.
This milestone marks a significant achievement in our ongoing efforts to advance ovarian cancer research using the ESGO Database.
As mentioned, ESGO had opened its first call for proposals for ovarian cancer studies within the ESGO Database. This initiative aimed to utilize existing data from the pilot project to address critical clinical questions related to advanced-stage and recurrent ovarian cancer. ESGO Consortium members who had contributed data to the pilot project were invited to submit study proposals leveraging the comprehensive data collected in the pilot study, "Validation of the ESGO Quality Indicators in Advanced Ovarian Cancer Surgery."
Eligible members submitted their initial proposals in September 2024. These submissions were carefully reviewed by the Scientific Evaluation Committee (SEC), and the top projects were invited to submit full proposals in November 2024. The final selection of studies was then announced at the ESGO Congress in Rome in February 2025, with the selected projects now moving forward into their research phases.
The centers whose proposals were chosen are now leading their respective projects in collaboration with ESGO and respective SEC members.
We are excited to see the progress and impact of these studies in the coming years!
For ESGO-accredited centers interested in joining the ESGO Consortium or learning more about future opportunities, please feel free to contact us at database@esgo.org!
Recently, ESGO has established the SEC (Scientific Evaluation Committee) for Ovarian Cancer, comprised of leading experts in gynecological oncology within the ESGO Consortium, who will rotate and are nominated for a period of 2 years. The SEC will rigorously evaluate each proposal based on predefined criteria and specific assessment scores. Their role ensures that the most promising and impactful studies are selected for further development.
Presenting our respected OC SEC members:
Need further information? Contact the ESGO Office
"We invest a lot in translational and clinical studies with new drugs but we sometimes forget that surgery is still the main cornerstone of our treatment. Registration and quality control are essential to improve care for our patients."
Prof. Toon Van GorpUniversity Hospital Leuven
"Lets all bring our patients together to improve the survival and outcome of patients with women cancers.We can only win if we fight together!"
Prof. Christina FotopoulouImperial College London
"Learning about the activities of other centers and sharing knowledge and experience is the main goal which I hope will bear fruit in the activities of the consortium."
Prof. Marius BidzinskiThe Maria Sklodowska-Curie Memorial Cancer Center
"The development of this database and network will have a lasting impact on the gynaecological oncology research in Europe. We are excited to be part of this."
Prof. Björn LampeFlorence-Nightingale Hospital, Dusseldorf
"Amazing idea and extraordinarily visionary in the future for our patients and also our medical environment. I am proud to be a part of the ESGO community."
Prof. Pawel KnappMedical University of Bialystok
ESGO Life-time award winner (2019)
ESGO Life-time award winner (2021)